Catalyze Capital
VC Fund
Amsterdam, The Netherlands
Catalyze Capital is a closed-end fund that invests in early-stage, creative firms across Europe. In keeping with our experience, the fund primarily focuses on Life Science, Sustainable, and Deep Tech technologies.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Catalyze Capital invests in
Stages Catalyze Capital invests in
Countries Catalyze Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Marlene Végh
|
|||
Peter Schoevers
|
|||
Tim Vink
|
|||
Investment Focus
Industry
- Health Care 1 (50%)
- Pharmaceutical 1 (50%)
Stage
- Series A 1 (50%)
- Series B 1 (50%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Marlene Végh
Chief Executive Officer
|
Chief Executive Officer | Total investments: 0 | Find email | |
|
Peter Schoevers
Founder and Managing Partner
|
Founder and Managing Partner | Total investments: 0 | Find email | |
|
Tim Vink
Chief Financial Officer
|
Chief Financial Officer | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Melt&Marble
|
Melt&Marble, formerly known as Biopetrolia, was founded patent holding firm for co-founder Professor Jens Nielsen’s research group. | $8.5M / Series A / Dec 08, 2025 | |
Gesynta Pharma
|
Founded in 2017, Gesynta Pharma bases its R&D on research from the Karolinska Institutet. The most advanced drug candidate, GS-248, reduces inflammation and increases blood flow in the microvasculature, thereby having the potential to provide improved treatments for several serious diseases. In an ongoing clinical proof-of-concept study,GS-248 is being evaluated for its capacity to normalize vascular blood flow and reduce pain in patients with the autoimmune disease systemic sclerosis. Positive results from this study may lead to a rapid broadening of the development program towards additional indications, for example cardiovascular diseases and rheumatic diseases other than systemic sclerosis. Major shareholders include Industrifonden, Linc, Hadean Ventures, and a number of successful life science entrepreneurs. For more information, please visit www.gesynta.se | $27.6M / Series B / Jan 20, 2025 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Catalyze Capital invest in?
Catalyze Capital invests primarily in Health Care and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 2 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Catalyze Capital?
Public channels for Catalyze Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Catalyze Capital?
The team at Catalyze Capital includes Marlene Végh (Chief Executive Officer), Peter Schoevers (Founder and Managing Partner) and Tim Vink (Chief Financial Officer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
